文献速递前列腺癌

前列腺癌局灶激光消融的5年结局

5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer.
PubMed 文献 · Urology · 2021-06-04

本研究纳入36例于2013至2015年接受磁共振引导下前列腺癌局灶激光消融(FLA)的男性,随访5年。中位随访71个月时,30例可评估患者中25例(83%)无失败生存,但10例(40%)出现野内复发,9例接受挽救性部分腺体消融。结论认为FLA对选择性病例可获得较高无失败生存率,但复发常见且常需挽救消融。

要点

  • 中位随访71个月,可评估患者中83%(25/30)无失败生存。
  • 野内复发率40%(10/25),其中9例接受挽救性部分腺体消融。
  • 5例接受挽救性全腺体或全身治疗,2例出现转移但PSA目前不可测。

核心结论

  • FLA对选择性前列腺癌病例可获得较高无失败生存率,定义为避免全腺体或全身治疗、转移或前列腺癌死亡。
  • 野内或野外复发常见,且常需挽救性消融。

研究设计与样本

  • 单中心回顾性队列,36例男性于2013至2015年接受磁共振引导下前列腺癌局灶激光消融(FLA)。
  • 随访包括直肠指检、PSA检测、多参数MRI及MR引导下活检。

主要发现

  • 36例入组者中6例失访,剩余30例中25例(83%)在中位随访71个月时无失败生存。
  • 25例无失败生存者中10例(40%)出现野内复发,9例接受挽救性部分腺体消融(FLA、冷冻治疗或高强度聚焦超声)。
  • 5例接受挽救性全腺体或全身治疗被判定为治疗失败;2例出现转移,接受放疗和ADT后PSA目前不可测。
  • 队列中无前列腺癌死亡。

临床怎么用

  • FLA可作为选择性局限性前列腺癌的局灶治疗选项,但需告知患者野内复发及挽救消融可能性较高。
  • 治疗后需通过PSA、多参数MRI及MR引导下活检进行密切随访监测复发。

局限性

  • 研究队列样本量小。
  • 治疗后2年缺乏标准化监测方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the oncologic outcomes 5 years following focal laser ablation (FLA) of localized prostate cancer. METHODS: 36 men underwent in-bore FLA of prostate cancer at our institution between 2013 and 2015. Follow up included digital rectal examination and PSA testing, multiparametric MRI, and MR-guided biopsies. The primary outcome of interest was failure-free survival (FFS), defined as avoidance of salvage whole gland treatment, systemic therapy, metastasis, or death from prostate cancer. RESULTS: Of the 36 men enrolled, 6 were ultimately lost to follow-up. Of the remaining 30, 25 (83%) have remained free from failure over a median follow-up of 71 months'. Among these patients, 10 (40%) developed in-field recurrence, with 9 undergoing salvage partial gland ablation with FLA, cryotherapy, or high-intensity focused ultrasound. Five patients underwent salvage whole gland or systemic treatment and were thus considered to have failed treatment. Two patients developed metastatic disease, and after receiving radiation and ADT, both currently have undetectable PSA levels. No patients in the cohort died from prostate cancer. Limitations include a small study cohort and lack of standardized surveillance protocols 2 years after treatment. CONCLUSION: FLA for select cases of prostate cancer provides high rates of FFS, defined as freedom from whole gland or systemic treatment, metastasis, or death from prostate cancer. However, in- or out-of-field recurrence is common and often necessitates salvage ablation.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chao B, Lepor H. 5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. Urology. 2021. PMID: 34090887. doi:10.1016/j.urology.2021.03.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。